• Min Gan, Zhuming Bao, and Juan Han.
• Medical Faculty, Yunnan University of Business Management.
• Medicine (Baltimore). 2021 Jan 8; 100 (1): e24278e24278.

BackgroundThe pathogenic mechanism and prevention of ventilator-associated pneumonia (VAP) are substantially improved over the past several decades, but VAP remains frequently seen among the critical cases. The Venner-PneuX endotracheal tube system (VPXETS) has been proved to perform better than standard endotracheal tubes (SET) in the prevention of VAP in some studies. Therefore, this systematic review is aimed at evaluating the effectiveness of VPXETS in order to prevent VAP.MethodsElectronic databases, including PubMed, WANFANG, CENTRAL, CNKI, EMBASE, and CINAHL, are used to search relevant randomized controlled trials for evaluating the therapeutic effect of VPXETS on preventing VAP from January 2011 to December 2020. To be specific, related studies are selected, data are extracted, risk of bias is assessed, and meta-analysis is conducted in succession.ResultsThe present review aims to assess the therapeutic effect of VPXETS on preventing VAP in intensive care units (ICUs). Our outcome measures include the incidence and side reaction of VAP.ConclusionsThe present review assesses related studies regarding the therapeutic effect of VPXETS on preventing VAP at ICUs.Dissemination And EthicsOur findings in this work are to be disseminated by means of peer-reviewed publication. No ethical approval is required in our review since it uses the published data. Moreover, anonymity is guaranteed during the data analysis process.Osf Registration NumberDOI 10.17605/OSF.IO/6BERJ.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

18 keywords...

hide…